Clifford Chance advised Pfizer on the IPO of its former Animal Health business ZOETIS. With the IPO, Pfizer has created the world’s largest standalone company fully devoted to animal health medicines and vaccines.
ZOETIS’ has more than 9,500 employees and its products are sold in more than 120 countries. ZOETIS’ turnover in 2011 amounted to approx. USD 4.2 billion. Clifford Chance advised Pfizer in particular with respect to pre-IPO restructuring measures and due diligence matters in more than 40 countries. These activities were coordinated by a Clifford Chance team in Dusseldorf, Germany, led by partner Dr. Christoph Holstein and comprised associate Hi-Zin Pak, counsel Daryl Fairbairn, senior associate Trevor Wedman and associates Dr. Philipp Heer and Dr. Dominik Kruse – all Corporate.
The international Clifford Chance team involved lawyers in eleven other Clifford Chance offices in Europe and Asia, i.e. in Amsterdam, Bucharest, Hongkong, Istanbul, London, Madrid, Moscow, Paris, Prague, Shanghai and Warsaw.
